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The biomaterials field constitutes a trans-
disciplinary activity in which synthetic or
naturally derived materials are utilized for
a variety of desired outcomes in living sys-
tems. Biomaterials may act as physical sup-
ports at times, providing a space in which
biological systems manifest their inherent
characteristics. More commonly, biomate-
rials actively participate in the performance
of a biological system, supporting or even
inducing desirable traits that would have
not been possible without the biomate-
rial. While biomaterials have become an
integral part of several industrial processes
and products, it is their medical use in
the body that fascinated and stimulated
our imagination. From simple entrapment
of enzymes (Chang, 1964), we witnessed
the creation of “bioartificial” organs com-
bining cells and materials (Chick et al.,
1977), followed by enzyme-sensitive bio-
materials by design (Ulbrich et al., 1980),
and engineered materials that matched the
physical (Urry et al., 1981) and cellular
requirements (Massia and Hubbell, 1991)
of injured tissues. We learned to utilize bio-
materials to control the release of small
molecules such as drugs (Schwartz et al.,
1968; Goodman and Banker, 1970) and
especially macromolecules such as pro-
teins (Langer and Folkman, 1976), which
stimulated us to explore unique thera-
pies. The potential of biomaterials is man-
ifested in diverse areas and every organ
in our bodies have benefited from them
in one form or another. To fulfill such
a broad translational promise, one needs
to rely on sound scientific and engineer-
ing practice and should be exceptionally
vigilant in fabricating and assessing the
constructed systems. Identifying a few uni-
fying (fundamental) principles for devel-
oping functional biomaterials is difficult
when the biomaterials are intended for
so many different uses, whether to stimu-
late our body’s surveillance system to fight
malignant cells or infections, to restore the
physical barrier in skin upon losing its
integrity, or to act as a blood conduit in
tiny channels. I believe that the challenges
facing functional biomaterials need to be
addressed in the context of intended appli-
cations. However, I would like to propose
that one should be mindful of two broad
challenges irrespective of the specific utility
of the biomaterials:
DOING GOOD: EFFICACY
New biomaterials give us a wonderful
opportunity to do good and improve the
status quo. It might be possible to probe
previously explored phenomena in a new
way and reveal hidden new phenomena
due to deployment of novel functional
biomaterials (McIntyre et al., 2004). We
might accelerate or enable healing that was
not previously possible when we combine
interactive biomaterials (Hubbell, 1995)
and potent inducers (Wozney et al., 1988).
Such beneficial outcomes might be possible
because biomaterials, when developed in
the right way, have the potential to domes-
ticate the nature, that is, to prevent its
detrimental aspects from taking over an
injury while enabling native processes to
undertake the healing activity. This should
excite the practitioners in the field, while
energizing the scientist, the engineer, and
the clinician to amalgamate their know-
how and come up with creative solutions.
The collective wisdom in the field can
foster us to come up with creative solu-
tions to our problems. These solutions may
come from simply borrowing ideas from
other fields and making use of bioma-
terials in a way that was not previously
imagined, such as the idea of “printing”
biological matter (Giordano et al., 1996).
Alternatively, we might have to rely on
novel chemical approaches to come up with
totally synthetic or semi-synthetic materi-
als with unique features and properties (Lee
et al., 2005; Verheyen et al., 2011). Endoge-
nous chemicals and architectures can guide
new biomaterials for previously unfore-
seen applications. While nature can guide
us toward uniquely beneficial features, we
could come up with features un-matched in
nature. We might have to explore physical
means of creating our functional materials
from “self” or “forced” assemblies (Chen
et al., 2014), or rely on biological sys-
tems to obtain synthetic biomaterials that
could not be envisioned before (Khalil and
Collins, 2010; Leszczak et al., 2014). For
the latter, one can envision cellular facto-
ries genetically engineered to synthesize,
assemble, and deposit complex materials
ready for tissue regeneration. Advanced
computational techniques will need to be
employed to better understand a regen-
eration process induced by biomaterials
(Mousavi et al., 2013) or gene delivery sys-
tems (Meneksedag-Erol et al., 2014), with
the intention of improving the design of
biomaterials. Temporal and spatial infor-
mation could be obtained with computa-
tional tools that are not readily available
by current experimental approaches, such
as the molecular basis for effective organi-
zation of self-assembling building blocks.
Doing good, however, needs to be under-
taken expeditiously and in the context of
financial and ethical pressures facing our
society. We do not have the luxury of
working at a leisurely pace while the soci-
ety is expecting cost-effective solutions to
partially met or unmet clinical problems.
This can be achieved by relying on inno-
vative biomaterials that are functional at
molecular level, fabricated devices that are
exquisitely designed and engineered at the
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nano–micro–meso scale and assessed com-
prehensively in relevant biological systems.
Let there be no doubt that we can ask
our biomaterials to jump higher and run
faster while saving lives and reducing our
financial burden.
DOING NO-HARM: SAFETY
One cannot overestimate the unpredictable
nature of living systems and their ability to
adopt and respond in the face of an intru-
sion. Nature has a way of reminding us
of the limitations of our good intentions,
whether we attempt to maintain our circu-
lation with artificial devices (clotting prob-
lem; Nosé et al., 1967), or deliver a gene to
support a failing physiology (genotoxicity;
Hacein-Bey-Abina et al., 2003). We need
to minimize or preferably eliminate the
adverse impact of biomaterials on biologi-
cal systems. This calls for using naturally
existing materials that can participate in
endogenous processes of metabolism and
elimination, or rely on building blocks that
are harmless to biological systems. We need
to keep a focus on different scales of bio-
logical systems when attempting to do no-
harm; the molecular scale where pertur-
bations of native biomolecular structures
need to be avoided, the cellular scale where
adverse effects manifest themselves as a
result of physical alterations in sub-cellular
structures, tissue/organ scales where the
special anatomical structures, such as the
junctional alignment of cells or tubu-
lar arrangement of blood vessels, should
not be compromised. These considerations
are amplified especially when we create
designer topographies or nano-structured
materials (Shvedova and Kagan, 2010, Koe-
gler et al., 2012). The best way to ensure
“no-harm” is to rely on degradable bioma-
terials that leave no traces of the biomate-
rial behind after the biomaterial completes
its task in the body (Bianco et al., 2011;
Dürig et al., 2011), and with degradation
products that are either excreted directly
or can enter into natural metabolic path-
ways. One cannot take a narrow approach
to safety; a complementary analysis of body
fluids, immune, and other surveillance sys-
tems have to be vigilantly probed to ensure
biomaterial compliance with the biologi-
cal system in the short term. Given the
possibility of altering the expression of a
wide range of genes whenever a thera-
peutic agent is introduced into the body,
long-term assessments for genotoxicity of
the biomaterials will be needed. At the end
of the day, we should be on guard to expect
a surprise from the nature, but also be con-
fident that progress will be made by over-
coming the presented obstacles. Preclinical
models, designed for the intended applica-
tion [after all, “biocompatibility” is inher-
ently linked to an application (Williams,
2008)] and characterized thoroughly, are
our best tools to pursue no-harm before
the biomaterials find their way to clinical
utility (Byrom et al., 2010; Muschler et al.,
2010; Fitzgerald et al., 2011).
FUTURE OF BIOMATERIALS
While we focus on doing good and ensur-
ing no-harm, it is clear to me that our
challenges are closely tied to the problems
that we are attempting to solve. This makes
it difficult to focus on a few overarching
or grand challenges, which thinly disperses
our collective wisdom throughout the field.
However, I believe that it is still possible
to identify several fundamental challenges
that are critical to the biomaterials field and
can lead to quantum leaps.
EMULATING NATURE FOR NEWMATERIALS
WITH UNIQUE FUNCTIONALITIES
Nature has given us materials that dis-
play the highest strength, strongest adhe-
sion, greatest flexibility, error-free dupli-
cation, induced degradation, and unique
on-demand features, to name a few qual-
ities. While we are learning to mimic
nature to reach its level of sophistica-
tion with synthetic biomaterials, we might
even do better than what we are emu-
lating when we apply our ingenuity and
tools fully. Super-adhesive biomaterials
(Brubaker and Messersmith, 2012), for
example, might one day seal vascular
defects at a fraction of the time that is
possible today after simply injecting the
biomaterials in the circulatory system. Arti-
ficial cells (Forster and Church, 2006),
whose development was put aside in favor
of native cells, might be deployed in the
fight against cancer in the future. An in-
depth understanding of natural materials,
especially their operational principles, is
paramount in this endeavor.
CONTROLLING THE ORGANIZATION OF
MATTER
Desired outcomes from biomaterials are
closely related to the organization of their
building blocks. For some applications,
organization at atomic scale is paramount,
while other applications may call for orga-
nization at a specific region of the nano-
or micro-scale. By assembly of right build-
ing blocks of a biomaterial at the appro-
priate scale, and then employing an engi-
neered and controllable fabrication process
for a functional device, we should be
able to fulfill the promise of the bioma-
terials more fully. Creating nanoparticles
with the ability to self-propel and move
toward, a chemo-attractant might be feasi-
ble with structures that are assembled from
functionally organized domains. Given the
inherent difficulties of fabricating struc-
turally controlled materials and devices for
the first time, computational approaches
could be a good start for exploring hypo-
thetical scenarios for the organized matter.
DESIGNING THE INTERFACE BETWEEN
BIOMATERIALS AND BIOLOGICAL SYSTEMS
TO MODULATE RESPONSES
It is well recognized that biomaterial sur-
faces are distinctly different from their bulk
features, be it their chemical composition
or physical properties. We should deliber-
ately control the surface features of bioma-
terials since all biological systems first get
exposed and subsequently respond to this
interface. For example, it may be possible to
create sensors that function endlessly due
to “stealth” surface features that make the
body ignore their presence while they sense
the immediate environment. We might
have to induce “tolerance” to biomaterials
for a stable, non-reactive interface, reminis-
cent of tissue transplantation (Bishop et al.,
2011). For reactive interfaces intended to
interact with their surroundings, the chal-
lenge of presenting biological cues in a
sea of adverse host factors (proteolytic
enzymes, protein adsorption, extracellu-
lar matrix deposition, etc.) remains to be
addressed. Will it be possible to design bio-
materials in such a way to target the right
cellular process for an amplified/stable
response, while the body is attempting to
isolate or neutralize the foreign entity?
RELYING ON INHERENT PHYSIOLOGICAL
MECHANISMS
We routinely relied on biostable materials
for permanent solutions at a time when lit-
tle was known about the inherent capacity
of our bodies to respond to undesired
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circumstances. With rapidly accumulat-
ing information on molecular and cellular
basis of pathophysiology and regenera-
tion, time is ripe to rely on our inher-
ent capabilities for healing, and biomate-
rials can be designed to take advantage of
innate processes to repair failing tissues and
organs. While this approach is beginning to
fulfill its promise in certain cases, such as
the bone and skin, its real return will be in
the repair of vital organs that evaded regen-
erative healing, such as heart and brain.
We will need to employ our entire arse-
nal in this regard to attract the right cells,
control the fate of invading cells, be it mor-
phogenetic differentiation, senescence, or
apoptosis, while the host response to our
intervention supports the intended out-
come. Controlling the mechanical features
of functional devices will be equally impor-
tant in this endeavor due to their impact
on cellular fate (Engler et al., 2006). How
mechano-regulation can be implemented
at a wound site, and not just under cul-
ture conditions, will be an important goal
to achieve. Biomaterial scaffolds designed
in the right way will play a significant role
in this endeavor.
IMPROVING OVER “GOLD” STANDARD
Our biomaterials, once fabricated into
functional devices, should do better than
the accepted practice when it comes to
efficacy, side-effects, and costs; the expec-
tation is to improve in all three aspects.
Innovative fabrication technologies capa-
ble of handling multimodal biomateri-
als and other biological materials, such
as regulatory molecules and cells, will
be required to achieve this goal. Simple-
to-produce DNA delivery systems func-
tioning better than viruses, “off-the-shelf”
kidneys for transplantation or artificial
cells secreting insulin on-demand, pro-
duced by large-scale cost-effective manu-
facturing processes, might 1 day find their
way to medical practice. Of course, strate-
gies to prevent opportunistic infections are
expected to be an integral part of each
intervention. Disruptive discoveries will
play a key role in setting up new gold
standards. Knowing that induced pluripo-
tent cells (Takahashi and Yamanaka, 2006)
can one day shake up the foundation of
tissue engineered devices, and microRNA
can add a new dimension into regenera-
tive medicine (Lee et al., 1993), we should
not shy away from unsettling ideas and
seek opportunities to actively incorporate
such ideas into our practice. The best way
to ensure improved gold standards is to
engage clinicians in biomaterials develop-
ment and overcome the challenges of coop-
erating across disciplines whose foci are
varied.
We expect the studies published in the
specialty section of Biomaterials, under
Frontiers in Bioengineering and Biotechnol-
ogy and Materials, to contribute to solving
our current challenges, while defining new
challenges for the future.
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